New research indicates that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who end traditional diet and exercise programs.
Published data in a major health publication shows that while overweight individuals often shed about a fifth of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.
"People using these drugs must be informed of the risk of fast rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
That rate of regain suggests a reversion to starting mass in about a year and a half.
Analyzing Therapies
The research, which reviewed 37 of studies involving thousands of participants, compared the effects of these new drugs with older methods.
Researchers emphasize that people who shed pounds through diet and exercise generally experience a slower creep back—approximately 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Nutrition scientists believe the way of the injections is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its endogenous hormone, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication leads to appetite is unsuppressed, making excessive eating far more likely."
An Ongoing Issue?
Health authorities recommend the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of weight regain, the therapy might need to be long-term.
This opinion is echoed by drug manufacturers, who say that the results "highlight the chronic nature of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the jabs report a sudden resurgence of cravings.
"It was like a switch activating and you're instantly ravenous," described one woman.
This challenge is compounded if individuals have not adopted sustainable lifestyle or habit changes during therapy.
Widespread Interest
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is more common among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers emphasize that while these medications are effective tools for shedding pounds, they are not a magic solution and maintained weight loss likely depends on integrated behavioural management.
